Day One Biopharmaceuticals, Inc. (DAWN): Price and Financial Metrics


Day One Biopharmaceuticals, Inc. (DAWN): $21.11

-0.64 (-2.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DAWN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

DAWN Stock Price Chart Interactive Chart >

Price chart for DAWN

DAWN Price/Volume Stats

Current price $21.11 52-week high $28.35
Prev. close $21.75 52-week low $5.44
Day low $20.92 Volume 434,200
Day high $21.98 Avg. volume 666,296
50-day MA $21.35 Dividend yield N/A
200-day MA $18.33 Market Cap 1.55B

Day One Biopharmaceuticals, Inc. (DAWN) Company Bio


Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.


DAWN Latest News Stream


Event/Time News Detail
Loading, please wait...

DAWN Latest Social Stream


Loading social stream, please wait...

View Full DAWN Social Stream

Latest DAWN News From Around the Web

Below are the latest news stories about DAY ONE BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate DAWN as an investment opportunity.

Thinking about buying stock in Duck Creek Technologies, CureVac, Day One Biopharmaceuticals, Bed Bath & Beyond, or Ocugen?

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DCT, CVAC, DAWN, BBBY, and OCGN. … Full story available on Benzinga.com

Benzinga | January 9, 2023

DAWN Rises on Promising Data in Brain Tumor Study

Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) are rising higher today after the company announced promising topline data from a Phase 2 study …

TipRanks | January 9, 2023

Day One Biopharma Shares Rise 13% After Positive Topline Results for Tovorafenib

By Chris Wack Day One Biopharmaceuticals Inc. shares were up 13% to $24.11 after the company said it saw positive topline results from an ongoing Phase 2…

MarketWatch | January 9, 2023

Day One stock surges 20% as brain tumor drug shows promise in mid-stage study

Day One Biopharmaceuticals (DAWN) reported data from an ongoing phase 2 trial of tovorafenib to treat recurrent or progressive pediatric low-grade glioma (pLGG).The main goal of the…

Seeking Alpha | January 9, 2023

Day One Biopharmaceuticals Shares Jump As Pediatric Brain Cancer Candidate Shows Encouraging Responses

Day One Biopharmaceuticals (NASDAQ: DAWN) announced topline results from the ongoing Phase 2 FIREFLY-1 trial evaluating tovorafenib (DAY101) as a monotherapy in recurrent or progressive pediatric low-grade glioma (pLGG). Pediatric low-grade glioma is the most common brain tumor diagnosed in children. Additional data will be submitted for presentation at an upcoming medical meeting in the second quarter of 2023. Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% were observ

Yahoo | January 9, 2023

Read More 'DAWN' Stories Here

DAWN Price Returns

1-mo -1.08%
3-mo 8.37%
6-mo -7.21%
1-year 53.64%
3-year N/A
5-year N/A
YTD -1.91%
2022 27.72%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.715 seconds.